SCIENCE@home

Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group

Y. Hirabayashi,Y. Munakata,M. Miyata,Y. Urata,Koichi Saito,H. Okuno,Masaaki Yoshida,T. Kodera,R. Watanabe,S. Miyamoto,T. Ishii,Shigeshi Nakazawa,H. Takemori,T. Ando,T. Kanno,M. Komagamine,Ichiro Kato,Yuichi Takahashi,A. Komatsuda,K. Endo,C. Murai,Y. Takakubo,T. Miura,Yukio Sato,K. Ichikawa,T. Konta,N. Chiba,T. Muryoi,Hiroko Kobayashi,H. Fujii,Y. Sekiguchi,A. Hatakeyama,K. Ogura,H. Sakuraba,T. Asano,H. Kanazawa,Eiji Suzuki,S. Takasaki,K. Asakura,K. Sugisaki,Yoko Suzuki,M. Takagi,Takahiro Nakayama,H. Watanabe,K. Miura,Yu Mori

Published 2016 in Modern Rheumatology

ABSTRACT

Abstract Objective: To evaluate the clinical and structural efficacy of tocilizumab (TCZ) during its long-term administration in patients with rheumatoid arthritis (RA). Methods: In total, 693 patients with RA who started TCZ therapy were followed for 3 years. Clinical efficacy was evaluated by DAS28-ESR and Boolean remission rates in 544 patients. Joint damage was assessed by calculating the modified total Sharp score (mTSS) in 50 patients. Results: When the reason for discontinuation was limited to inadequate response or adverse events, the 1-, 2-, and 3-year continuation rates were 84.0%, 76.8%, and 72.2%, respectively. The mean DAS28-ESR was initially 5.1 and decreased to 2.5 at 6 months and to 2.2 at 36 months. The Boolean remission rate was initially 0.9% and increased to 21.7% at 6 months and to 32.2% at 36 months. The structural remission rates (ΔmTSS/year ≤ 0.5) were 68.8%, 78.6%, and 88.9% within the first, second, and third years, respectively. The structural remission rate at 3 years (ΔmTSS ≤ 1.5) was 66.0%, and earlier achievement of swollen joint count (SJC) of 1 or less resulted in better outcomes. Conclusions: TCZ was highly efficacious, and bone destruction was strongly prevented. SJC was an easy-to-use indicator of joint destruction.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-27 of 27 references · Page 1 of 1

CITED BY

Showing 1-17 of 17 citing papers · Page 1 of 1